We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Development of pemphigus vulgaris following mRNA SARS‐CoV‐19 BNT162b2 vaccination in an 89‐year‐old patient.
- Authors
Knechtl, G.V.; Seyed Jafari, S.M.; Berger, T.; Rammlmair, A.; Feldmeyer, L.; Borradori, L.
- Abstract
The patient has provided written consent for the publication of the case. Most PV patients are aged 40-60 years at diagnosis.1 The mean age of pemphigus patients was 62.5 years in the Swiss cohort.3 However, the development of PV after COVID-19 vaccination may be simply coincidental in our patient. Development of pemphigus vulgaris following mRNA SARS-CoV-19 BNT162b2 vaccination in an 89-year-old patient.
- Subjects
PEMPHIGUS vulgaris; PEMPHIGUS; COVID-19 vaccines; VACCINATION; MESSENGER RNA; BULLOUS pemphigoid
- Publication
Journal of the European Academy of Dermatology & Venereology, 2022, Vol 36, Issue 4, pe251
- ISSN
0926-9959
- Publication type
Article
- DOI
10.1111/jdv.17868